Clinical trials in Ottignies-Louvain-La-Neuve

47 clinical trials in Ottignies-Louvain-La-Neuve, Belgium across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Ottignies-Louvain-La-Neuve at a glance

clinical trials

Paediatric trials0
Research sites1

Quick filters

47 trials in Ottignies-Louvain-La-Neuve

Open in trial search

Non-small cell lung cancer+1

Recruiting

Phase III Randomized Study of Rilvegostomig vs. Pembrolizumab with Platinum-based Chemotherapy in PD-L1 Expressing Metastatic Squamous NSCLC

Registered drugNo placebo

Phase III Randomized Study of Rilvegostomig vs. Pembrolizumab with Platinum-based Chemotherapy in PD-L1 Expressing Metastatic Squamous NSCLC

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:AstraZeneca AB

Contact Research Centre

Ischaemic stroke

Recruiting

A Study to Test if Rinvecalinase Alfa is Safe and Works for Treating Acute Ischemic Stroke in Patients with Moderate Stroke Severity

Investigational

A Study to Test if Rinvecalinase Alfa is Safe and Works for Treating Acute Ischemic Stroke in Patients with Moderate Stroke Severity

Investigational

Belgium

Participants:18–64 years · 65+ years
Substances:Rinvecalinase alfa
Sponsor:Diamedica Therapeutics Inc.

Contact Research Centre

Hormone receptor positive HER2 negative breast cancer

Recruiting

Study of personalized treatment using drug combination therapy for young women with early stage hormone receptor-positive breast cancer based on gene expression testing

Registered drugNo placebo

Study of personalized treatment using drug combination therapy for young women with early stage hormone receptor-positive breast cancer based on gene expression testing

Registered drugNo placebo

Belgium

Participants:18–64 years
Substances:Anastrozole
Sponsor:Unicancer

Contact Research Centre

Acute respiratory failure

Recruiting

Study on Tozorakimab for Patients Hospitalized with Severe Viral Lung Infections Needing Oxygen

Investigational

Study on Tozorakimab for Patients Hospitalized with Severe Viral Lung Infections Needing Oxygen

Investigational

Belgium

Participants:18–64 years · 65+ years
Substances:Tozorakimab
Sponsor:AstraZeneca AB

Contact Research Centre

Non-small cell lung cancer

Recruiting

Study comparing rilvegostomig plus chemotherapy versus pembrolizumab plus chemotherapy for first-line treatment in patients with metastatic non-squamous lung cancer with PD-L1 expression

Registered drugNo placebo

Study comparing rilvegostomig plus chemotherapy versus pembrolizumab plus chemotherapy for first-line treatment in patients with metastatic non-squamous lung cancer with PD-L1 expression

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:AstraZeneca AB

Contact Research Centre

Non-small cell lung cancer

Recruiting

Study of LY3537982, pembrolizumab, and a drug combination for patients with advanced non-small cell lung cancer and a KRAS G12C mutation

Registered drug

Study of LY3537982, pembrolizumab, and a drug combination for patients with advanced non-small cell lung cancer and a KRAS G12C mutation

Registered drug

Belgium

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Eli Lilly & Co.

Contact Research Centre

Coagulation factor X level

Recruiting

VMX-C001 in Patients Taking Factor Xa Inhibitors Who Need Urgent Surgery or an Invasive Procedure With High Bleeding Risk

InvestigationalNo placebo

VMX-C001 in Patients Taking Factor Xa Inhibitors Who Need Urgent Surgery or an Invasive Procedure With High Bleeding Risk

InvestigationalNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:VMX-C001
Sponsor:VarmX B.V.

Contact Research Centre

Acute kidney injury

Recruiting

A study testing how well AZD4144 works and how safe it is for adults with acute kidney injury caused by sepsis

Investigational

A study testing how well AZD4144 works and how safe it is for adults with acute kidney injury caused by sepsis

Investigational

Belgium

Participants:18–64 years · 65+ years
Sponsor:AstraZeneca AB

Contact Research Centre

Hormone-refractory prostate cancer

Recruiting

A Study of JNJ-78278343 Compared to Placebo for Patients with Advanced Prostate Cancer That No Longer Responds to Hormone Treatment

Investigational

A Study of JNJ-78278343 Compared to Placebo for Patients with Advanced Prostate Cancer That No Longer Responds to Hormone Treatment

Investigational

Belgium

Participants:18–64 years · 65+ years
Substances:JNJ-78278343
Sponsor:Janssen Cilag International

Contact Research Centre

Breast cancer+2

Recruiting

Study of PF-07248144 and fulvestrant in adults with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer who had progression after CDK4/6 inhibitor therapy

Registered drugNo placebo

Study of PF-07248144 and fulvestrant in adults with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer who had progression after CDK4/6 inhibitor therapy

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Everolimus
Sponsor:Pfizer Inc.

Contact Research Centre

Acute myeloid leukaemia

Recruiting

Study of Bleximenib, Venetoclax, and Azacitidine Treatment for Newly Diagnosed Acute Myeloid Leukemia Patients Ineligible for Intensive Chemotherapy

Registered drug

Study of Bleximenib, Venetoclax, and Azacitidine Treatment for Newly Diagnosed Acute Myeloid Leukemia Patients Ineligible for Intensive Chemotherapy

Registered drug

Belgium

Participants:18–64 years · 65+ years
Substances:Azacitidine
Sponsor:Janssen Cilag International

Contact Research Centre

Abdominal infection+3

Recruiting

Study on High-Dose Short-Course Antibiotics for Critically Ill Patients with Pneumonia, Intra-Abdominal, or Bloodstream Infections: Ceftriaxone, Linezolid, and Cefotaxime

Registered drugNo placebo

Study on High-Dose Short-Course Antibiotics for Critically Ill Patients with Pneumonia, Intra-Abdominal, or Bloodstream Infections: Ceftriaxone, Linezolid, and Cefotaxime

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Cefotaxime
Sponsor:Universitair Ziekenhuis Gent

Contact Research Centre

Other cities in Belgium

The busiest research cities in the country

All 170 cities in Belgium

Clinical research in Ottignies-Louvain-La-Neuve

What the registry says about research in the country

01 Hematology & Oncology Research

Groundbreaking clinical trials focusing on multiple myeloma treatments, specifically targeting patients with relapsed or refractory conditions. The research evaluates innovative combination therapies including talquetamab and daratumumab administration.

Blood Cancer Therapeutics
Novel Drug Combinations
Treatment Resistance

This comparative study aims to advance treatment options for patients who have undergone at least one prior line of therapy, potentially offering new hope for those with difficult-to-treat blood cancers.

Back to Belgium All countries

Clinical trials in Ottignies-Louvain-La-Neuve

47 trials in Ottignies-Louvain-La-Neuve

Non-small cell lung cancer+1

Phase III Randomized Study of Rilvegostomig vs. Pembrolizumab with Platinum-based Chemotherapy in PD-L1 Expressing Metastatic Squamous NSCLC

Ischaemic stroke

A Study to Test if Rinvecalinase Alfa is Safe and Works for Treating Acute Ischemic Stroke in Patients with Moderate Stroke Severity

Hormone receptor positive HER2 negative breast cancer

Study of personalized treatment using drug combination therapy for young women with early stage hormone receptor-positive breast cancer based on gene expression testing

Acute respiratory failure

Study on Tozorakimab for Patients Hospitalized with Severe Viral Lung Infections Needing Oxygen

Non-small cell lung cancer

Study comparing rilvegostomig plus chemotherapy versus pembrolizumab plus chemotherapy for first-line treatment in patients with metastatic non-squamous lung cancer with PD-L1 expression

Non-small cell lung cancer

Study of LY3537982, pembrolizumab, and a drug combination for patients with advanced non-small cell lung cancer and a KRAS G12C mutation

Coagulation factor X level

VMX-C001 in Patients Taking Factor Xa Inhibitors Who Need Urgent Surgery or an Invasive Procedure With High Bleeding Risk

Acute kidney injury

A study testing how well AZD4144 works and how safe it is for adults with acute kidney injury caused by sepsis

Hormone-refractory prostate cancer

A Study of JNJ-78278343 Compared to Placebo for Patients with Advanced Prostate Cancer That No Longer Responds to Hormone Treatment

Breast cancer+2

Study of PF-07248144 and fulvestrant in adults with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer who had progression after CDK4/6 inhibitor therapy

Acute myeloid leukaemia

Study of Bleximenib, Venetoclax, and Azacitidine Treatment for Newly Diagnosed Acute Myeloid Leukemia Patients Ineligible for Intensive Chemotherapy

Abdominal infection+3

Study on High-Dose Short-Course Antibiotics for Critically Ill Patients with Pneumonia, Intra-Abdominal, or Bloodstream Infections: Ceftriaxone, Linezolid, and Cefotaxime

Filter the trials

Other cities in Belgium

Clinical research in Ottignies-Louvain-La-Neuve

Prefer not to search? Our Concierge searches the trials for you.

Clinical trials in Ottignies-Louvain-La-Neuve

47 trials in Ottignies-Louvain-La-Neuve

Non-small cell lung cancer+1

Breast cancer+2

Abdominal infection+3

Other cities in Belgium

Related

Clinical research in Ottignies-Louvain-La-Neuve

Prefer not to search? Our Concierge searches the trials for you.